NCT07916779
Erectile Function PRESERVation in Definitive Radiotherapy for Prostate Cancer by MRI-Enhanced Adaptive Sparing of the Neurovascular Bundle
Not Yet Recruiting · Not Applicable · University of Zurich · registry updated 2026-11-04
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Radiotherapy is a standard and highly effective treatment for prostate cancer that is confined to the prostate gland. One modern approach, called stereotactic body radiotherapy (SBRT), delivers treatment in just five sessions and has been shown to control prostate cancer as well as longer treatment schedules. Large clinical studies have demonstrated excellent cancer control rates after SBRT. Although SBRT is effective, some men experience worsening erectile function after treatment. Researchers believe that reducing radiation exposure to the nerves and blood vessels involved in erections, known as the neurovascular bundles (NVBs), may help preserve sexual function. The EF-PRESERVE study is evaluating whether a specialized MRI-guided treatment approach can safely reduce radiation dose to these structures while still delivering effective treatment to the prostate cancer.
Inclusion
- Age ≥18 years
- Histologically confirmed, low- or intermediate risk localized prostate cancer eligible for definitive prostate SBRT according to NCCN criteria as (Appendix 1):
- PSA \<20 ng/ml and
- At least at one side the DIL ≥5 mm from the NVB
- WHO/ECOG performance status 0-2
- Sexually active patients (i.e. satisfactory penetrative intercourse over the last 4 weeks)
Exclusion
- DIL within \<5 mm to NVB at both sides
- High risk localized prostate cancer according to NCCN criteria as:
- PSA ≥20 ng/ml or
- Non-localized prostate cancer (i.e. cN1 or cM1)
- Insufficient erectile function preventing satisfactory penetrative intercourse (i.e. erectile dysfunction CTCAE (v6.0) Grade 3)
- Sexually inactive patients (i.e. no penetrative intercourse over the last 4 weeks).